Cabot (NYSE:CBT) Stock Price Expected to Rise, Mizuho Analyst Says

Cabot (NYSE:CBT) had its price target upped by equities researchers at Mizuho from $75.00 to $80.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the specialty chemicals company’s stock. Mizuho’s price objective would indicate a potential downside of 5.32% from the stock’s previous close.

Several other research analysts also recently commented on CBT. UBS Group increased their price objective on shares of Cabot from $74.00 to $81.00 and gave the company a “neutral” rating in a report on Thursday, February 5th. Jefferies Financial Group reiterated a “buy” rating and issued a $85.00 target price on shares of Cabot in a research report on Wednesday, February 4th. Finally, Zacks Research raised Cabot from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 27th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $75.00.

Cabot Trading Up 7.0%

Cabot stock opened at $84.49 on Wednesday. The stock has a market cap of $4.41 billion, a P/E ratio of 14.59, a PEG ratio of 10.00 and a beta of 0.78. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.67 and a quick ratio of 1.09. Cabot has a 1 year low of $58.33 and a 1 year high of $83.71. The firm’s 50 day moving average price is $73.67 and its 200-day moving average price is $70.26.

Cabot (NYSE:CBT) last issued its earnings results on Tuesday, May 5th. The specialty chemicals company reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.14. The firm had revenue of $904.00 million during the quarter, compared to analyst estimates of $900.31 million. Cabot had a net margin of 8.62% and a return on equity of 22.82%. Cabot’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.90 earnings per share. Cabot has set its FY 2026 guidance at 6.000-6.50 EPS. On average, equities analysts predict that Cabot will post 6.27 earnings per share for the current fiscal year.

Institutional Trading of Cabot

Several hedge funds have recently made changes to their positions in CBT. NewEdge Advisors LLC increased its stake in Cabot by 2,559.5% during the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock worth $82,000 after acquiring an additional 947 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Cabot by 32.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock valued at $36,802,000 after purchasing an additional 108,645 shares during the last quarter. Empowered Funds LLC raised its holdings in Cabot by 102.6% during the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after buying an additional 14,260 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Cabot by 3.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock worth $10,145,000 after buying an additional 4,048 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in Cabot by 409.0% during the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after buying an additional 364 shares during the period. 93.18% of the stock is currently owned by hedge funds and other institutional investors.

Cabot News Roundup

Here are the key news stories impacting Cabot this week:

• Positive Sentiment: Quarterly results beat expectations — adjusted EPS of $1.61 topped the consensus $1.47 and revenue of $904M was roughly in line, showing the company outperformed street estimates this quarter. Cabot (CBT) Surpasses Q2 Earnings Estimates
• Positive Sentiment: Battery materials and segment performance showing strength — management cited battery materials momentum and meaningful EBITDA contribution; Reinforcement Materials EBIT was $93M and Performance Chemicals EBIT $59M, supporting growth narrative. Cabot Corporation Reports Second Quarter Fiscal Year 2026 Results
• Positive Sentiment: Board raised the quarterly dividend by 5% (new quarterly $0.4725; annualized $1.89), boosting yield and returning cash to shareholders. Cabot Corporation Board Increases Dividend
• Neutral Sentiment: FY?2026 EPS guidance set to $6.00–$6.50 (street consensus ~6.24) — range essentially encompasses the consensus, so guidance is not a clear positive or negative surprise for investors.
• Neutral Sentiment: Company hosted an earnings call and posted slides/transcript for investors to assess details and modeling assumptions. Listen to Conference Call
• Negative Sentiment: Revenue and EPS are down year?over?year (revenue down ~3.4%; GAAP EPS declined vs prior year), highlighting near?term demand softness in parts of the business. Cabot Corporation Reports Second Quarter Fiscal Year 2026 Results
• Negative Sentiment: Company announced plans to pursue asset optimization, including potential closures of manufacturing operations in South America and Europe — possible near?term restructuring costs and local consultation risks. Cabot Corporation Reports Second Quarter Fiscal Year 2026 Results

Cabot Company Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.